Typ 2 diabetes

The Bright study demonstrated similar efficacy and safety of Toujeo^® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin¹.

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

På den här sidan kan du lära dig mer om diabetes och träning, både vid typ 1 och typ 2.

2025 infaller Ramadan mellan 28 februari och 29 mars. Vi har tagit fram material för att hjälpa dig att stötta din patient med diabetes som vill fasta under Ramadan.

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Practical Guidance based on the 2022 ADA/EASD Guidelines.

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.

Injektionsfilm för din patient som behandlas med Toujeo DoubleStar